Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy

Thomas O Bergmeijer; Gerrit Ja Vos; Daniël Mf Claassens; Paul Wa Janssen; Remko Harms; Richard van der Heide; Folkert W Asselbergs; Jurriën M Ten Berg; Vera Hm Deneer

doi:10.2217/pgs-2018-0013

Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy

Thomas O Bergmeijer, Gerrit Ja Vos, Daniël Mf Claassens, Paul Wa Janssen, Remko Harms, Richard van der Heide, Folkert W Asselbergs, Jurriën M Ten Berg, Vera Hm Deneer

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

AIM: A tailored antiplatelet strategy based on CYP2C19 genotype may reduce atherothrombotic and bleeding events. We describe our experience with CYP2C19 genotyping, using on-site TaqMan or Spartan genotyping or shipment to a central laboratory.

METHODOLOGY: Data from two ongoing projects were used: Popular Risk Score project (non-urgent percutaneous coronary intervention patients) and the Popular Genetics study (ST-segment elevation myocardial infarction patients). For both projects, the time to genotyping result was calculated.

RESULTS: In the Popular Risk Score project (n = 2556), median time from blood collection to genotyping result was 4:04 h. In the Popular Genetics study (n = 1038), median time from randomization to genotyping result was 2:24 h.

CONCLUSION: CYP2C19 genotyping is feasible in everyday clinical practice, both in the acute and non-acute settings.

Original language	English
Pages (from-to)	621-628
Number of pages	8
Journal	Pharmacogenomics
Volume	19
Issue number	7
DOIs	https://doi.org/10.2217/pgs-2018-0013
Publication status	Published - May 2018

Keywords

CYP2C19
PCI
STEMI
genotyping
lopidogrel
personalized medicinepharmacogenomics
ticagrelor

Access to Document

10.2217/pgs-2018-0013

Cite this

@article{11a53d0fc291444fbec3377f95c1d261,

title = "Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy",

abstract = "AIM: A tailored antiplatelet strategy based on CYP2C19 genotype may reduce atherothrombotic and bleeding events. We describe our experience with CYP2C19 genotyping, using on-site TaqMan or Spartan genotyping or shipment to a central laboratory.METHODOLOGY: Data from two ongoing projects were used: Popular Risk Score project (non-urgent percutaneous coronary intervention patients) and the Popular Genetics study (ST-segment elevation myocardial infarction patients). For both projects, the time to genotyping result was calculated.RESULTS: In the Popular Risk Score project (n = 2556), median time from blood collection to genotyping result was 4:04 h. In the Popular Genetics study (n = 1038), median time from randomization to genotyping result was 2:24 h.CONCLUSION: CYP2C19 genotyping is feasible in everyday clinical practice, both in the acute and non-acute settings.",

keywords = "CYP2C19, PCI, STEMI, genotyping, lopidogrel, personalized medicinepharmacogenomics, ticagrelor",

author = "Bergmeijer, {Thomas O} and Vos, {Gerrit Ja} and Claassens, {Dani{\"e}l Mf} and Janssen, {Paul Wa} and Remko Harms and {der Heide}, {Richard van} and Asselbergs, {Folkert W} and {Ten Berg}, {Jurri{\"e}n M} and Deneer, {Vera Hm}",

note = "Publisher Copyright: {\textcopyright} 2018 2018 Future Medicine Ltd.",

year = "2018",

month = may,

doi = "10.2217/pgs-2018-0013",

language = "English",

volume = "19",

pages = "621--628",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Taylor and Francis Ltd.",

number = "7",

}

TY - JOUR

T1 - Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy

AU - Bergmeijer, Thomas O

AU - Vos, Gerrit Ja

AU - Claassens, Daniël Mf

AU - Janssen, Paul Wa

AU - Harms, Remko

AU - der Heide, Richard van

AU - Asselbergs, Folkert W

AU - Ten Berg, Jurriën M

AU - Deneer, Vera Hm

PY - 2018/5

Y1 - 2018/5

N2 - AIM: A tailored antiplatelet strategy based on CYP2C19 genotype may reduce atherothrombotic and bleeding events. We describe our experience with CYP2C19 genotyping, using on-site TaqMan or Spartan genotyping or shipment to a central laboratory.METHODOLOGY: Data from two ongoing projects were used: Popular Risk Score project (non-urgent percutaneous coronary intervention patients) and the Popular Genetics study (ST-segment elevation myocardial infarction patients). For both projects, the time to genotyping result was calculated.RESULTS: In the Popular Risk Score project (n = 2556), median time from blood collection to genotyping result was 4:04 h. In the Popular Genetics study (n = 1038), median time from randomization to genotyping result was 2:24 h.CONCLUSION: CYP2C19 genotyping is feasible in everyday clinical practice, both in the acute and non-acute settings.

AB - AIM: A tailored antiplatelet strategy based on CYP2C19 genotype may reduce atherothrombotic and bleeding events. We describe our experience with CYP2C19 genotyping, using on-site TaqMan or Spartan genotyping or shipment to a central laboratory.METHODOLOGY: Data from two ongoing projects were used: Popular Risk Score project (non-urgent percutaneous coronary intervention patients) and the Popular Genetics study (ST-segment elevation myocardial infarction patients). For both projects, the time to genotyping result was calculated.RESULTS: In the Popular Risk Score project (n = 2556), median time from blood collection to genotyping result was 4:04 h. In the Popular Genetics study (n = 1038), median time from randomization to genotyping result was 2:24 h.CONCLUSION: CYP2C19 genotyping is feasible in everyday clinical practice, both in the acute and non-acute settings.

KW - CYP2C19

KW - PCI

KW - STEMI

KW - genotyping

KW - lopidogrel

KW - personalized medicinepharmacogenomics

KW - ticagrelor

U2 - 10.2217/pgs-2018-0013

DO - 10.2217/pgs-2018-0013

M3 - Article

C2 - 29701129

SN - 1462-2416

VL - 19

SP - 621

EP - 628

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 7

ER -

Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy

Abstract

Keywords

Access to Document

Fingerprint

Cite this